Latest Zoledronic acid Stories
An osteoporosis drug proven to save lives after hip fractures may do so by strengthening the body's immune system, according to geriatrics researchers at Duke University Medical Center.
THOUSAND OAKS, Calif., July 7 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that a pivotal, Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the treatment of bone metastases in 2,049 patients with advanced breast cancer met its primary and secondary endpoints and demonstrated superior efficacy compared to Zometa.
- Single infusion of Reclast increases bone mass for two years in postmenopausal women with osteopenia, a condition that can lead to osteoporosis(1) - Approximately 22 million women in US have osteopenia, or low bone mass, putting them at increased risk of fractures of hip, spine and wrist(2,3) - Reclast already approved as once-yearly infusion for treatment of postmenopausal osteoporosis(1) EAST HANOVER, N.J., June 1 /PRNewswire/ -- Reclast(R) (zoledronic acid) Injection has been approved...
A team of 24 researchers from the U.S., Europe, Taiwan and Japan and led by University of Illinois scientists has engineered a new anti-cancer agent that is about 200 times more active in killing tumor cells than similar drugs used in recent clinical trials.
A U.S.-led team of scientists says it has developed an anti-cancer agent that's about 200 times more effective than similar drugs used in recent studies. University of Illinois researchers said the new agent belongs to a class of drugs called bisphosphonates -- compounds originally developed to treat osteoporosis and other bone diseases. Previous studies found the bisphosphonate drug zoledronate, significantly reduced the recurrence of breast cancer in pre-menopausal women with...
ADA creates brochures with National Osteoporosis Foundation CHICAGO, March 9 /PRNewswire-USNewswire/ -- Dental patients who have been alarmed or confused by recent news reports about how osteoporosis medications might affect their oral health now have a brochure to help them separate fact from fiction.
Austrian scientists say they've found the drug Zometa is effective in reducing the risk of early breast cancer re-occurrence or death in premenopausal women. The research by the Austrian Breast & Colorectal Cancer Study Group is said to be the first large, randomized, Phase III clinical trial to show Zometa (zoledronic acid) offers significant protection against the return of early breast cancer in premenopausal women. The scientists said Zometa, along with post-surgery hormonal therapy,...
Zoledronic acid may shrink breast tumors when used used in addition to chemotherapy, scientists meeting in San Antonio said. Zoledronic acid is primarily targeted to bone and metastasis within the bone marrow microenvironment, but it may also be enhancing the response in the primary breast tumor, Dr.
According to a preliminary study reported Thursday at a cancer conference in Texas, new research adds fresh hope that a drug that strengthens bones might also fight breast cancer.
Adding Zometa to chemotherapy prior to surgery led to an additional 33% reduction in tumor size, resulting in fewer mastectomies New data are first to demonstrate direct effect of Zometa to help shrink primary tumors; further evidence of Zometa as a potential anticancer therapy EAST HANOVER, N.J., Dec.